Online first
Original Article
Published online: 2024-07-01

open access

Page views 176
Article views/downloads 81
Get Citation

Connect on Social Media

Connect on Social Media

Predictive value of early-phase heart rate reduction for subsequent recovery of left ventricular systolic function in heart failure with reduced ejection fraction

Ryutaro Yoshimura1, Ou Hayashi2, Takeshi Horio1, Ryosuke Fujiwara1, yujiro Matsuoka1, Go Yokouchi1, Yuya Sakamoto1, Naoki Matsumoto1, Kohei Fukuda1, Masahiro Shimizu1, Yasuhirio Izumiya2, Minoru Yoshiyama23, Daiju Fukuda2, Kohei Fujimoto1, Noriaki Kasayuki14
Pubmed: 38949392

Abstract

Introduction: Predictors of heart failure with recovered ejection fraction (HFrecEF) remain to be fully elucidated. This study investigated the impact of heart rate and its change on the recovery of left ventricular ejection fraction (LVEF) in heart failure with reduced ejection fraction (HFrEF).

Material and methods: From 398 outpatients who had a history of hospitalisation for heart failure, 138 subjects diagnosed as HFrEF (LVEF < 40%) on heart failure hospitalisation were enrolled and longitudinally surveyed. During follow-up periods more than one year, 64 and 46 patients were identified as HFrecEF (improved LVEF to ≥ 40% and its increase of ≥ 10 points) and persistent HFrEF, respectively.

Results: In the overall subjects, the reduction of heart rate through the observation periods was closely correlated with the improvement of LVEF (r = –0.508, p < 0.001). Heart rate on hospital admission for heart failure was markedly higher in patients with HFrecEF (112 ± 26 bpm) than in those with persistent HFrEF (90±18 bpm). Whereas heart rate at the first outpatient visit after discharge was already lower in the HFrecEF group (80 ± 13 vs. 85 ± 13 bpm in the persistent HFrEF group). A multivariate logistic regression analysis revealed that the decrease in heart rate from admission to the first visit after discharge was a significant determinant of HFrecEF (p < 0.001), independently of confounding factors such as ischemic heart disease and baseline LVEF and left ventricular dimension.

Conclusions: Our findings suggest that heart rate reduction in the early phase after heart failure onset is a powerful independent predictor of the subsequent recovery of LVEF in HFrEF patients.

Article available in PDF format

View PDF Download PDF file

References

  1. Tsutsui H, Isobe M, Ito H, et al. Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. Circ J. 2019; 83(10): 2084–2184.
  2. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021; 23(3): 352–380.
  3. Wilcox JE, Fang JC, Margulies KB, et al. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020; 76(6): 719–734.
  4. Lupón J, Díez-López C, de Antonio M, et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail. 2017; 19(12): 1615–1623.
  5. Park CS, Park JJ, Mebazaa A, et al. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction. J Am Heart Assoc. 2019; 8(6): e011077.
  6. Ghimire A, Fine N, Ezekowitz JA, et al. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. Eur Heart J. 2019; 40(26): 2110–2117.
  7. Park JJ, Mebazaa A, Hwang IC, et al. Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes. J Am Heart Assoc. 2020; 9(12): e015009.
  8. Zhang X, Sun Y, Zhang Y, et al. Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction. ESC Heart Fail. 2021; 8(6): 5383–5391.
  9. Torii Y, Kusunose K, Hirata Y, et al. Left Atrial Strain Associated with Functional Recovery in Patients Receiving Optimal Treatment for Heart Failure. J Am Soc Echocardiogr. 2021; 34(9): 966–975.e2.
  10. Fox K, Ford I, Steg PG, et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372(9641): 817–821.
  11. Böhm M, Swedberg K, Komajda M, et al. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010; 376(9744): 886–894.
  12. Castagno D, Skali H, Takeuchi M, et al. Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. Journal of the American College of Cardiology. 2012; 59(20): 1785–1795.
  13. Takada T, Sakata Y, Miyata S, et al. CHART-2 Investigators. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study. Eur J Heart Fail. 2014; 16(3): 309–316.
  14. Li SJ, Sartipy U, Lund LH, et al. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. Circ Heart Fail. 2015; 8(5): 871–879.
  15. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001; 103(10): 1428–1433.
  16. Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008; 101(6): 865–869.
  17. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009; 150(11): 784–794.
  18. Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744): 875–885.
  19. Ceconi C, Freedman SB, Tardif JC, et al. BEAUTIFUL Echo-BNP Investigators. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011; 146(3): 408–414.
  20. Tardif JC, O'Meara E, Komajda M, et al. SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011; 32(20): 2507–2515.
  21. Tsutsui H, Momomura SI, Yamashina A, et al. J-SHIFT Study Investigators. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study. Circ J. 2019; 83(10): 2049–2060.
  22. Nakao K, Horio T, Yoshimura R, et al. Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure. Heart Vessels. 2021; 36(8): 1175–1182.
  23. Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6): 982–992.
  24. Otsuka K, Nakanishi K, Shimada K, et al. Associations of sensitive cardiac troponin-I with left ventricular morphology, function and prognosis in end-stage renal disease patients with preserved ejection fraction. Heart Vessels. 2018; 33(11): 1334–1342.
  25. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004; 64(16): 1757–1765.